IRCT20200105046010N68
Recruiting
未知
In- Vivo Bioequivalence study of Daclaasvir/Sofosbuvir 60/400 mg Actero Middle East Pharma (DATEX 400/60 mg Tab.) with brand drug (Sofosbovir/Daclatasivir® 400/60 mg, Mylan, Germany) in Iranian healthy volunteers.
Actero middle east Pharm Co.0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Actero middle east Pharm Co.
- Enrollment
- 24
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General health
- •Body mass index between18\-28
- •Informed consent
- •Being at the age of 18\-55 years old
Exclusion Criteria
- •A history of cardiovascular disease
- •A history of liver \& kidney disease
- •Alcohol \& Drug addiction
- •Hypersensitivity to the drug
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Investigating the in vivo bioequivalence of Sofosbuvir/Daclatasvir tabletIn the present study, the products will be administered to healthy volunteers..IRCT20220211053992N8Tabriz University of Medical Sciences24
Completed
Phase 2
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1IRCT20200324046850N2Abadan University of Medical Sciences62
Completed
Phase 3
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000
Completed
Phase 3
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
Completed
Not Applicable
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldHealth Condition 1: B182- Chronic viral hepatitis CHealth Condition 2: D56- ThalassemiaCTRI/2020/06/025910Riten Kumar Samadder70